

**CURRICULUM VITAE**

**Name:** GEORGE KOLIOS MD PhD  
**Nationality:** Greek  
**Address:** Democritus University of Thrace  
Faculty of Medicine  
Dragana, Alexandroupolis,  
GR-68100, GREECE  
Tel/ FAX: +3025510-30368  
E-mail: [gkolios@med.duth.gr](mailto:gkolios@med.duth.gr)  
Website: <http://utopia.duth.gr/~gkolios>

**Present Posts:**

- Professor of Pharmacology, Faculty of Medicine, Democritus University of Thrace (June 2008 - onward).
- Head of the Laboratories of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Democritus University of Thrace (September 2008 - onward).
- Director of the Master's degree Program "Clinical Pharmacology and Therapeutics", Democritus University of Thrace (October 2009 - onward).
- Vice-President of the Faculty of Medicine, Democritus University of Thrace (September 2013 - onward).

**Qualifications:**

- Degree of Medicine, Medical School of Athens, Greece (March 1980).
- Specialization in Gastroenterology, Greek State Board (May 1990).
- Doctorate of Philosophy (Ph.D.), School of Medicine, University of Athens, Greece (May 1992).
- Doctorate of Philosophy (Ph.D.), School of Pharmacology, University of Bath, UK. (February 1998).

**Previous appointments Greece:**

- Registrar in Internal Medicine, 401 Military Hospital, Athens Greece, (August 1981 - October 1982).
- General Practitioner, Health Center of Vourgareli, Arta, Greece (November 1982- October 1984).
- Registrar in Internal Medicine, Sismanogleion Hippokration General Hospital, Athens, Greece (February 1985- February 1996).
- Registrar in Gastroenterology, 2nd Dept of Medicine, Hippokration General Hospital, University of Athens, Greece (April 1986 - March 1990).
- Senior Registrar in Gastroenterology, Hippokration General Hospital, Athens, Greece (May 1991 - December 1997).
- Assistant Professor of Gastroenterology, Faculty of Medicine, University of Crete (March 2001 – June 2008).
- Head of the Division of Clinical Pharmacology, Faculty of Medicine, University of Crete (September 2002 – June 2008).
- Member of the Scientific Board for Drug Approval, Greek National Organization for Medicines (September 2008 - November 2013).

**Previous appointments abroad:**

- Registrar in Gastroenterology, Royal United Hospital, Bath UK (June 1990 - July 1991).
- Research Fellow (Grade II), Department of Pharmacy and Pharmacology, University of Bath, UK, (December 1995 – May 1996).
- Consultant Gastroenterologist, Royal United Hospital, Bath, UK (January 1998 – December 2000).
- Senior Clinical Research Fellow, Department of Pharmacy and Pharmacology, University of Bath, UK, (January 1998 – December 2000).
- Researcher, Novartis Pharmaceuticals Ltd United Kingdom, (June 1999 – November 2000).
- Visiting Professor of Pharmacology, Department of Pharmacology, University of Bath, UK (January 2001 - December 2013).
- Visiting Scientist (Sabbatical), Laboratory of Molecular Immunology, Mucosal Immunobiology Section, National Institute of Health (NIH), Bethesda, Maryland, U.S.A. (January 2007-November 2007).
- Visiting Scientist (Sabbatical), Immunology Institute, Mount Sinai School of Medicine, U.S.A. (November 2007-March 2008).

**Grants:**

- 1994-1995: £ 35.000, National Association for Crohn and Colitis, UK. (Chemokine production by human colonic epithelial cells in inflammatory bowel disease).
- 1995-1998: Drachma 3.000.000, Hellenic Society of Gastroenterology. (Chemokine expression in the mucosa of inflammatory bowel disease patients; modulation by T-cell derived cytokines).
- 1996-1997: £55.000, Astra Foundation, UK. (Mechanisms of mucosal injury in inflammatory bowel disease).
- 1997-1998: £55,000, Astra Foundation, UK (Regulation of chemokines and inducible nitric oxide synthase by cytokines in Inflammatory Bowel Disease-IBD).
- 1999-2000: £ 120.000, Novartis, UK (The role of chemokines in the fibrotic process in IBD).
- 2002-2003: £ 15.000, Wellcome Trust, UK (Investigate the cross-talk between colonic epithelial cells, IEL and myofibroblasts and its relevance to IBD).
- 2005-2007: €45,200, 25% Greek Ministry of National Education and 75% European Social Fund (The impact of chemokines in the fibrotic process of Crohn's disease; the role of myofibroblasts).
- 2006-2009: €12,000, Greek Ministry of Health (The regulatory role of angiogenic and angiostatic CXC chemokines on colon cancer. Factors regulating the tumor growth and metastasis).
- 2009-2015: €130,000, GlaxoSmithKline, Greece (Inflammatory mediators and cell populations interplay in the pathogenesis of idiopathic pulmonary fibrosis and pulmonary hypertension), in collaboration with Professor D. Bouros, DUTH, Greece.
- 2013-2015: €95,000, BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), National Strategic Reference Framework, Greece/European Union.

**Awards:**

- **2006:** 1st prize (€1,500) FALK Foundation Symposium 153, Immunoregulation in Inflammatory Bowel Diseases for the work " *Expression of a spliced variant of*

*CXCR3 chemokine receptor and its chemokine ligands in Crohn's disease patients; a regulatory effect of cytokines"*, May 6-7, 2006, Berlin Germany.

- **2013:** 3rd prize (€10,000) in SFEE Innovation Project, with a project aiming "to unravel the potential of using adipose-derived adult stem cells for autologous transplantation, in an effort to combat incurable lung diseases", November 24, 2013, Athens Greece,
- **2014:** National Scholar Award at 22nd United European Gastroenterology Week for the work "primary intestinal myofibroblasts express the TNF-like cytokine *TL1A/TNFSF15* following stimulation with pro-inflammatory mediators", October 18-22, 2014, Vienna Austria.

#### **Memberships:**

- Full member of the Greek Society of Gastroenterology (November 1990).
- Full member of the British Society for Immunology (November 1998).
- Full member of the European Society of Gastrointestinal and Abdominal Radiology (May 2005).
- Full member of the International Society for Mucosal Immunology (September 2007).
- Full member of the European Crohn's and Colitis Organisation (May 2008)
- Full member of the Greek Society of Pharmacology (February 2009).
- President of the Greek Society for Mucosal Immunology and Immuno-Pharmacology (February 2015).

#### **Member of Editorial Boards:**

- Annals of Gastroenterology, Associate Editor
- European Journal of Pharmacology, Editorial Board
- Clinical Medicine Reviews in Therapeutics, Editorial Board
- Global Journal of Stem Cell Biology and Transplantation, Editorial Board
- Journal of Medical Case Reports, Editorial Board

#### **Selected Publications (Pubmed):**

- 1) **Kolios G**, Brown Z, Robson RL, Robertson DAF, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. *British Journal of Pharmacology* 1995; 116:2866-2872.
- 2) **Kolios G**, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). *Gastrointestinal Endoscopy* 1995; 42:336-339.
- 3) **Kolios G**, Robertson DAF, Jordan NJ, Minty A, Caput D, Ferrara P, Westwick J. Interleukin-8 production by the human colon epithelial cell line HT-29: Modulation by interleukin -13. *British Journal of Pharmacology* 1996; 119:351-359.
- 4) Wright K, Ward SG, **Kolios G**, Westwick J. Activation of phosphatidylinositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. *Journal of Biological Chemistry* 1997; 272:12626-12633.
- 5) Davis AJ, **Kolios G**, Alvey CG, Robertson DA. Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephalosporin in the prophylaxis of high-risk patients. *Alimentary Pharmacology and Therapeutics* 1998; 12:207-211.

- 6) **Kolios G**, Rooney N, Murphy CT, Robertson DAF, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: Modulation by T-lymphocyte derived cytokines. *Gut* 1998; 43:56-63.
- 7) **Kolios G**, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. *Hepatogastroenterology* 1998; 45:1601-1609.
- 8) Jordan NJ, **Kolios G**, Abbot SE, Sinai MA, Thompson DA, Petraki K, Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. *Journal of Clinical Investigation* 1999; 104:1061-1069.
- 9) **Kolios G**, Wright KL, Jordan NJ, Leithead BJ, Robertson DAF, Westwick J. C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: Differential effect of T-lymphocyte derived cytokines. *European Journal of Immunology* 1999; 29:530-536.
- 10) Wright K, **Kolios G**, Westwick J, Ward SG. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. *Journal of Biological Chemistry* 1999; 274:17193-17201.
- 11) **Kolios G**, Wright KL, Linehan JD, Robertson DA, Westwick J. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. *Hepatogastroenterology* 2000; 47:714-717.
- 12) Weaver SA, Russo MP, Wright KL, **Kolios G**, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. *Gastroenterology* 2001; 120:1117-1127.
- 13) **Kolios G**, Valatas V, Psilopoulos D, Petraki K, Kouroumalis E. Depletion of non specific esterase activity in the colonic mucosa of patients with ulcerative colitis. *European Journal of Clinical Investigation* 2002; 32:265-273.
- 14) Valatas V, Xidakis C, Roumpaki H, **Kolios G**, Kouroumalis EA. Isolation of rat Kupffer cells: a combined methodology for highly purified primary cultures. *Cell Biology International* 2003; 27:67-73.
- 15) Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. *Immunology* 2004; 113:427-437.
- 16) Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, **Kolios G**, Kouroumalis EA. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology* 2004; 16:1147-1152.
- 17) Notas G, **Kolios G**, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. *Journal of Hepatology* 2004; 40:792-798.
- 18) Valatas V, **Kolios G**, Manousou P, Notas G, Xidakis C, Diamantis I, Kouroumalis E. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. *British Journal of Pharmacology* 2004; 141:477-487.
- 19) Valatas V, **Kolios G**, Manousou P, Xidakis C, Notas G, Ljumovic D, Kouroumalis EA. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. *Regulatory Peptides* 2004; 120:215-225.
- 20) Vasilaki A, Papadaki T, Notas G, **Kolios G**, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. *Investigative Ophthalmology & Visual Science* 2004; 45:1499-1506.

- 21) Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, **Kolios G**, Robertson DA, Ward SG. Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. *British Journal of Pharmacology* 2004; 141:1091-1097.
- 22) Xidakis C, **Kolios G**, Valatas V, Notas G, Mouzas I, Kouroumalis E. Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. *Anticancer Research* 2004; 24:833-841.
- 23) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action? *American Journal Physiology - Gastrointestinal & Liver Physiology* 2005; 288:G261-G267.
- 24) Dimoulios P, **Kolios G**, Notas G, Matrella E, Xidakis C, Koulentaki M, Tsagarakis N, Kouroumalis A, Kouroumalis E. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. *Alimentary Pharmacology and Therapeutics* 2005; 21:227-234.
- 25) Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, **Kolios G**, Kouroumalis E. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. *Digestive Diseases and Sciences* 2005; 50:935-941.
- 26) Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, **Kolios G**, Ward SG. The Chemokines CXCL9, CXCL10, and CXCL11 Differentially Stimulate G{alpha}i-Independent Signaling and Actin Responses in Human Intestinal Myofibroblasts. *Journal of Immunology* 2005; 175:5403-5411.
- 27) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. *Free Radical Biology & Medicine* 2005; 39:1560-1569.
- 28) Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, **Kolios G**, Kouroumalis E, Margioris AN, Gravanis A. Neuropeptide urocortin and its receptors are expressed in rat kupffer cells. *Neuroendocrinology* 2006; 84:49-57.
- 29) **Kolios G**, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. *World Journal of Gastroenterology* 2006; 12:7413-7420.
- 30) **Kolios G**, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I, Kouroumalis E. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. *European Journal of Clinical Investigation* 2006; 36:720-729.
- 31) **Kolios G**, Kotzampassi K, Manousou P, Paramythiotis D, Papanastasiou H, Drygiannakis I, Notas G, Tsagarakis N, Eleftheriadis E, Kouroumalis E. Enteral nutrition affects nitric oxide production in peripheral blood and liver after a postoperative lipopolysaccharide-induced endotoxemia in rats. *Nutrition* 2007; 23:575-581.
- 32) Xidakis C, Mastrodinou N, Notas G, Renieri E, **Kolios G**, Kouroumalis E, Thermos K. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. *Regulatory Peptides* 2007; 143:76-82.
- 33) Damaskos D, **Kolios G**. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. *British Journal of Clinical Pharmacology* 2008; 65:453-467.
- 34) **Kolios G**, Valatas V, Manousou P, Xidakis C, Notas G, Kouroumalis E. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. *Molecular and Cellular Biochemistry* 2008; 319:91-98.

- 35) Manousou P, **Kolios G**, Drygiannakis I, Pyrovolaki K, Bourikas L, Papadaki HA, Kouroumalis E. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction. *Journal of Gastroenterology and Hepatology* 2008; 23:1823-1833.
- 36) Bourikas LA, **Kolios G**, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, Manousou P, Klironomos S, Mouzas IA, Kouroumalis E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. *British Journal of Pharmacology* 2009; 157:362-370.
- 37) Galazios G, Papazoglou D, Tsikouras P, **Kolios G**. Vascular endothelial growth factor gene polymorphisms and pregnancy. *Journal of Maternal-Fetal & Neonatal Medicine* 2009; 22:371-378.
- 38) Kotzampassi K, **Kolios G**, Manousou P, Kazamias P, Paramythiotis D, Papavramidis TS, Heliadis S, Kouroumalis E, Eleftheriadis E. Oxidative stress due to anesthesia and surgical trauma: Importance of early enteral nutrition. *Molecular Nutrition & Food Research* 2009; 53:770-779.
- 39) Paschos KA, **Kolios G**, Chatzaki E. The corticotropin-releasing factor system in inflammatory bowel disease: Prospects for new therapeutic approaches. *Drug Discovery Today* 2009; 14:713-720.
- 40) Kefalakes E, Stylianides TJ, Amanakis G, **Kolios G**. Exacerbation of Inflammatory Bowel Diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or Reality? *European Journal of Clinical Pharmacology* 2009; 65:963-70.
- 41) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. A concentration dependent effect of Ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. *European Journal of Pharmacology* 2010; 640: 1-7.
- 42) Manousou P, **Kolios G**, Valatas V, Drygiannakis I, Bourikas L, Pyrovolaki K, Koutroubakis I, Papadaki HA, Kouroumalis E. Increased expression of Chemokine receptor CCR3 and its ligands in ulcerative colitis; the role of colonic epithelial cells in in vitro studies. *Clinical & Experimental Immunology* 2010; **162**: 337-347.
- 43) Kapetanakis S, Drygiannakis I, Kazakos K, Papanas N, **Kolios G**, Kouroumalis E, Verettas DA. Serum TGF- $\beta$  2 and TGF- $\beta$  3 are increased and positively correlated to pain, functionality and radiographic staging in osteoarthritis. *Orthopedics* 2010; 33:551.
- 44) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma cells (HepG2). *World Journal of Gastroenterology*; 2011; 17:313-321.
- 45) Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M, Mitroulis I, Rafail S, Vradelis S, Sigalas I, Wu YQ, Speletas S, **Kolios G**, Ritis K. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. *Journal of Immunology* 2011; 186:6568-6575.
- 46) Chrysanthopoulou A, Mitroulis I, Kambas K, Skendros P, Kourtzelis I, Vradelis S, **Kolios G**, Aslanidis S, Doumas M, Ritis K. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation. *Arthritis & Rheumatism* 2011; 63:3586-3597.
- 47) Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, **Kolios G**, Bouros D. Effect and safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis. *Pulmonary Medicine* 2011; 2011:849035.

- 48) Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, **Kolios G**, Paspaliaris V, Kakagia D, Kotsianidis I, Froudarakis M, Bouros D. Stem cell therapy for Idiopathic Pulmonary Fibrosis. A protocol proposal. *Journal of Translational Medicine* 2011; 9:182.
- 49) Tzouvelekis A, Galanopoulos N, Bouros E, **Kolios G**, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of Mycophenolate mofetil or sodium in systemic sclerosis - associated interstitial lung disease. A meta-analysis. *Pulmonary Medicine* 2012; 2012:143637.
- 50) Domvri K, Zarogoulidis P, Porpodis K, Koffa M, Lambropoulou M, Kakolyris S, **Kolios G**, Zarogoulidis K, Chatzaki E. Gene therapy in liver diseases: State-of-the-art and future perspectives. *Current Gene Therapy* 2012; 12:463-483.
- 51) Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, **Kolios G**, Kouroumalis E. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. *Journal of Crohn's and Colitis* 2013; 7:286-300.
- 52) Valatas V, He J, Rivollier A, **Kolios G**, Kitamura K, Kelsall BL. Host-dependent control of early regulatory and effector T cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis. *Mucosal Immunology* 2013; 6:601-611.
- 53) **Kolios G**, Moodley Y. Introduction to Stem Cells and Regenerative Medicine. *Respiration* 2013; 85:3-10.
- 54) Manousou P, **Kolios G**, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. *Clinical & Experimental Immunology* 2013; 172:9-15.
- 55) Chatzaki E, Anton PA, Million M, Lambropoulou M, Costantinidis T, **Kolios G**, Taché Y, Grigoriadis DE. CRF Receptor 2 in human colonic mucosa: down-regulation in Ulcerative Colitis. *World Journal of Gastroenterology* 2013; 19:1416-1423.
- 56) Pazaitou-Panayiotou K, Chemonidou C, Poupi A, Koureta M, Kaprara A, Lambropoulou M, Constantinidis TC, Galaktidou G, Koffa M, Kiziridou A, Kakolyris S, **Kolios G**, Kortsaris A, Chatzaki E. Gonadotropin-Releasing Hormone neuropeptides and receptor in human breast cancer: correlation to poor prognosis parameters. *Peptides* 2013; 42:15-24.
- 57) Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentis AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, **Kolios G**, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. *Clinical Chemistry and Laboratory Medicine* 2013; 51:1505-1510.
- 58) Paschos KA, Chouridou E, Koureta M, Lambropoulou M, **Kolios G**, Chatzaki E. The Corticotropin Releasing Factor system in the liver: expression, actions and possible implications in hepatic physiology and pathology. *Hormones (Athens)* 2013; 12:236-245
- 59) Drosos I, **Kolios G**. Stem cells in liver regeneration and their potential clinical applications. *Stem Cell Reviews and Reports* 2013; 9:668-684.
- 60) Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, **Kolios G**, Bouros D. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal

- vascular fraction in Idiopathic Pulmonary Fibrosis. *Journal of Translational Medicine* 2013; 11:171.
- 61) Valatas V, Vakas M, **Kolios G**. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. *American Journal of Physiology, Gastrointestinal Liver Physiology* 2013; 305:G763-G785.
  - 62) Lalidou F, **Kolios G**, Drosos GI. Bone Infections and Bone Graft Substitutes for Local Antibiotic Therapy. *Surgical Technology International* 2014; 24:353-362.
  - 63) Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, **Kolios G**, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C. GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery *Bioconjugate Chemistry* 2014; 25:813-823.
  - 64) Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, **Kolios G**, Miltiades P, Paraskakis E, Antoniadis A, Kotsianidis I, Bouros D. Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients. *Lung*. 2014; 192:849-855.
  - 65) Lalidou F, **Kolios G**, Tavridou A, Drosos GI. Bone grafts as carriers for local antibiotic delivery for the treatment and prevention of bone infections. *Surgical Technology International* 2014; 25:239-245.
  - 66) Drosos I, Tavridou A, **Kolios G**. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. *Metabolism-Clinical & Experimental* 2015; 64:476-481.
  - 67) Valatas V, Bamias G, **Kolios G**. Experimental Colitis Models: Insights into the Pathogenesis of Inflammatory Bowel Disease and Translational Issues. *European Journal of Pharmacology* 2015; 759:253-264.
  - 68) Sertaridou E, Papaioannou V, **Kolios G**, Pneumatikos I. Gut failure in critical care: old school versus new school. *Annals of Gastroenterology* 2015; 28:309-322.
  - 69) Fotiadis K, Filidou E, Arvanitidis K, Vassilis Valatas V, Stavrou G, Basdanis G, Paspaliaris V, **Kolios G**, Kotzampassi K. Intraperitoneal application of phospholipids for the prevention of post-operative adhesions: a possible role of myofibroblasts. *Journal of Surgical Research* 2015; 197:291-300.
  - 70) **Kolios G**. Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? *Digestive Disease Science* 2016;61:330-331.
  - 71) **Kolios G**. Animal models of inflammatory bowel disease: how useful are they really? *Current Opinion Gastroenterology* 2016;32:251-257.
  - 72) Kotanidis L, Nikolettos K, Petousis S, Asimakopoulos B, Chatzimitrou E, **Kolios G**, Nikolettos N. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. *Journal of Endocrinological Investigation* 2016; 39:1459-1464.
  - 73) Bamias G, Filidou E, Goukos D, Valatas V, Arvanitidis K, Panagopoulou M, Kouklakis G, Daikos G, Ladas SD, **Kolios G**. Crohn's Disease-Associated Mucosal Factors Regulate the Expression of TNF-like Cytokine 1A (TL1A) and its Receptors in Primary Subepithelial Intestinal Myofibroblasts and Intestinal Epithelial Cells. *Translational Research* 2017;180:118-130.
  - 74) Panagopoulou M, Lambropoulou M, Balgkouranidou I, Nena E, Karaglani M, Nicolaidou C, Asimaki A, Konstantinidis T, Constantinidis TC, **Kolios G**, Kakolyris S, Agorastos T, Chatzaki E. Gene promoter methylation and protein expression of



- BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. *Tumor Biology* 2017; in press.
- 75) Valatas V, Filidou E, Drygianakis I, **Kolios G**. Stromal and Immune cells in Gut Fibrosis: the Myofibroblast and the Scarface. *Annals of Gastroenterology* 2017; in press.
- 76) Dovrolis N, **Kolios G**, Spyrou G, Maroulakou I. Laying in silico pipelines for drug repositioning; a paradigm in ensemble analysis for neurodegenerative diseases. *Drug Discovery Today* 2017; in press.

March 2017

George Kolios, MD PhD